ALK and lung carcinoma: The subsequent systematic review focuses on the utilization of LCOs as in vitro models to assess drug sensitivity, encompassing chemotherapeutic agents and targeted drugs against common lung cancer biomarkers such as EFGR, ALK, and KRAS.